Objectives

• Explain the role of HDL in overall cardiovascular risk reduction and how HDL-C particle size may relate to lipid metabolism
• Describe various cardiac biomarkers and their implications for patient screening and management
• Review the role of cardiac resynchronization therapy in managing patients with heart failure
• Discuss strategies for evaluating and treating patients with symptomatic AF
• Describe the need for accurate diagnosis and risk stratification of stable CAD patients, and interpret findings from COURAGE and BARI 2D.
• Describe the role of imaging in the diagnosis and risk of cardiovascular disease
• Examine clinical trial results of novel oral anticoagulants used in the prevention of AF-related stroke
• Discuss how new and emerging stent technologies have evolved and their potential to improve patient outcomes in CAD
• Summarize state of the art treatment for aortic and peripheral vascular disease